Literature DB >> 22103242

Dronedarone prevents microcirculatory abnormalities in the left ventricle during atrial tachypacing in pigs.

A Bukowska1, M Hammwöhner, A Sixdorf, L Schild, I Wiswedel, F-W Röhl, C Wolke, U Lendeckel, C Aderkast, S Bochmann, R K Chilukoti, J Mostertz, P Bramlage, A Goette.   

Abstract

BACKGROUND AND
PURPOSE: Atrial fibrillation induces ischaemic microcirculatory flow abnormalities in the ventricle, contributing to the risk for acute coronary syndromes. We evaluated the effect of dronedarone on ventricular perfusion during rapid atrial pacing (RAP). EXPERIMENTAL APPROACH: Coronary and fractional flow reserve (CFR/FFR) were measured in the left anterior descending artery in 29 pigs. Six received RAP, six received RAP with dronedarone (RAP/D), seven received dronedarone alone, four received RAP with amiodarone (RAP/A), and six received neither (sham). In ventricular tissue, oxidative stress/ischaemia-related gene and protein expression was evaluated by RT-PCR and Western blotting; Isoprostanes were measured by GC-MS procedures. KEY
RESULTS: CFR was decreased in the RAP group, compared with other groups. FFR was not different between groups. Effective refractory period was reduced in RAP compared with RAP/D. RAP-activated PKC phosphorylation tended to be decreased by dronedarone (P= 0.055) RAP induced NOX-1 and NOX-2 protein and the mRNA for hypoxia-inducible factor-1α (HIF-1α). Dronedarone reduced the pacing-dependent increase in the expression of NOX-2 protein and of HIF-1α mRNA. The oxidative stress marker, F(2)-isoprostane, was increased by RAP and this increase was attenuated by dronedarone. Other oxidative stress/ischaemia-related genes were induced by RAP compared with sham and were decreased by dronedarone treatment. In HL1 cells, dronedarone significantly inhibited the increased phosphorylation of PKCα after oxidative stress, with an almost significant effect (P= 0.059) on that after RAP. CONCLUSIONS AND IMPLICATIONS: Dronedarone abolished RAP-induced ventricular microcirculatory abnormalities by decreasing oxidative stress/ischaemia-related gene and protein expression in the ventricle.
© 2011 The Authors. British Journal of Pharmacology © 2011 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22103242      PMCID: PMC3417422          DOI: 10.1111/j.1476-5381.2011.01784.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  60 in total

1.  HL-1 cells: a cardiac muscle cell line that contracts and retains phenotypic characteristics of the adult cardiomyocyte.

Authors:  W C Claycomb; N A Lanson; B S Stallworth; D B Egeland; J B Delcarpio; A Bahinski; N J Izzo
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-17       Impact factor: 11.205

Review 2.  Redox regulation of NF-kappa B activation.

Authors:  L Flohé; R Brigelius-Flohé; C Saliou; M G Traber; L Packer
Journal:  Free Radic Biol Med       Date:  1997       Impact factor: 7.376

3.  Elevated levels of 8-iso-prostaglandin F2alpha in pericardial fluid of patients with heart failure: a potential role for in vivo oxidant stress in ventricular dilatation and progression to heart failure.

Authors:  Z Mallat; I Philip; M Lebret; D Chatel; J Maclouf; A Tedgui
Journal:  Circulation       Date:  1998-04-28       Impact factor: 29.690

4.  Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1.

Authors:  J A Forsythe; B H Jiang; N V Iyer; F Agani; S W Leung; R D Koos; G L Semenza
Journal:  Mol Cell Biol       Date:  1996-09       Impact factor: 4.272

5.  Effect of dronedarone on cardiovascular events in atrial fibrillation.

Authors:  Stefan H Hohnloser; Harry J G M Crijns; Martin van Eickels; Christophe Gaudin; Richard L Page; Christian Torp-Pedersen; Stuart J Connolly
Journal:  N Engl J Med       Date:  2009-02-12       Impact factor: 91.245

6.  Oxidative stress: a possible pathogenesis of atrial fibrillation.

Authors:  Cong-Xin Huang; Yu Liu; Wen-Fang Xia; Yan-Hong Tang; He Huang
Journal:  Med Hypotheses       Date:  2008-12-21       Impact factor: 1.538

Review 7.  Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics.

Authors:  J A Berliner; M Navab; A M Fogelman; J S Frank; L L Demer; P A Edwards; A D Watson; A J Lusis
Journal:  Circulation       Date:  1995-05-01       Impact factor: 29.690

8.  CXCL8/IL8 stimulates vascular endothelial growth factor (VEGF) expression and the autocrine activation of VEGFR2 in endothelial cells by activating NFkappaB through the CBM (Carma3/Bcl10/Malt1) complex.

Authors:  Daniel Martin; Rebeca Galisteo; J Silvio Gutkind
Journal:  J Biol Chem       Date:  2008-12-26       Impact factor: 5.157

9.  Dronedarone in high-risk permanent atrial fibrillation.

Authors:  Stuart J Connolly; A John Camm; Jonathan L Halperin; Campbell Joyner; Marco Alings; John Amerena; Dan Atar; Álvaro Avezum; Per Blomström; Martin Borggrefe; Andrzej Budaj; Shih-Ann Chen; Chi Keong Ching; Patrick Commerford; Antonio Dans; Jean-Marc Davy; Etienne Delacrétaz; Giuseppe Di Pasquale; Rafael Diaz; Paul Dorian; Greg Flaker; Sergey Golitsyn; Antonio Gonzalez-Hermosillo; Christopher B Granger; Hein Heidbüchel; Josef Kautzner; June Soo Kim; Fernando Lanas; Basil S Lewis; Jose L Merino; Carlos Morillo; Jan Murin; Calambur Narasimhan; Ernesto Paolasso; Alexander Parkhomenko; Nicholas S Peters; Kui-Hian Sim; Martin K Stiles; Supachai Tanomsup; Lauri Toivonen; János Tomcsányi; Christian Torp-Pedersen; Hung-Fat Tse; Panos Vardas; Dragos Vinereanu; Denis Xavier; Jun Zhu; Jun-Ren Zhu; Lydie Baret-Cormel; Estelle Weinling; Christoph Staiger; Salim Yusuf; Susan Chrolavicius; Rizwan Afzal; Stefan H Hohnloser
Journal:  N Engl J Med       Date:  2011-11-14       Impact factor: 91.245

10.  Acute atrial tachyarrhythmia induces angiotensin II type 1 receptor-mediated oxidative stress and microvascular flow abnormalities in the ventricles.

Authors:  Andreas Goette; Alicja Bukowska; Dobromir Dobrev; Jan Pfeiffenberger; Henning Morawietz; Denis Strugala; Ingrid Wiswedel; Friedrich-Wilhelm Röhl; Carmen Wolke; Sybille Bergmann; Peter Bramlage; Ursula Ravens; Uwe Lendeckel
Journal:  Eur Heart J       Date:  2009-03-05       Impact factor: 29.983

View more
  13 in total

1.  MMI-0100 inhibits cardiac fibrosis in myocardial infarction by direct actions on cardiomyocytes and fibroblasts via MK2 inhibition.

Authors:  Lei Xu; Cecelia C Yates; Pamela Lockyer; Liang Xie; Ariana Bevilacqua; Jun He; Cynthia Lander; Cam Patterson; Monte Willis
Journal:  J Mol Cell Cardiol       Date:  2014-10-01       Impact factor: 5.000

Review 2.  Perspectives and challenges of antioxidant therapy for atrial fibrillation.

Authors:  Iveta Gasparova; Peter Kubatka; Radka Opatrilova; Martin Caprnda; Slavomira Filipova; Luis Rodrigo; Leone Malan; Ioana Mozos; Miroslava Rabajdova; Vladimir Nosal; Nazarii Kobyliak; Vanda Valentova; Daniel Petrovic; Mariusz Adamek; Peter Kruzliak
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-11-29       Impact factor: 3.000

3.  Integration of "omics" techniques: Dronedarone affects cardiac remodeling in the infarction border zone.

Authors:  Ravi K Chilukoti; Josefine Lendeckel; Katrin Darm; Alicja Bukowska; Andreas Goette; Marc Sühling; Kirsten Utpatel; Barbara Peters; Georg Homuth; Uwe Völker; Carmen Wolke; Christian Scharf; Uwe Lendeckel
Journal:  Exp Biol Med (Maywood)       Date:  2018-07

Review 4.  WNT signaling in atrial fibrillation.

Authors:  Carmen Wolke; Elmer Antileo; Uwe Lendeckel
Journal:  Exp Biol Med (Maywood)       Date:  2021-02-27

5.  Oxidative Stress and Microcirculatory Flow Abnormalities in the Ventricles during Atrial Fibrillation.

Authors:  Andreas Goette; Alicja Bukowska; Christopher H Lillig; Uwe Lendeckel
Journal:  Front Physiol       Date:  2012-07-05       Impact factor: 4.566

6.  Pleiotropic effects of antiarrhythmic agents: dronedarone in the treatment of atrial fibrillation.

Authors:  Jordi Heijman; Gerd Heusch; Dobromir Dobrev
Journal:  Clin Med Insights Cardiol       Date:  2013-08-11

7.  Effect of dronedarone on clinical end points in patients with atrial fibrillation and coronary heart disease: insights from the ATHENA trial.

Authors:  Ron Pisters; Stefan H Hohnloser; Stuart J Connolly; Christian Torp-Pedersen; Lisa Naditch-Brûlé; Richard L Page; Harry J G M Crijns
Journal:  Europace       Date:  2013-09-26       Impact factor: 5.214

Review 8.  Atrial fibrillation: effects beyond the atrium?

Authors:  Rohan S Wijesurendra; Barbara Casadei
Journal:  Cardiovasc Res       Date:  2015-01-12       Impact factor: 10.787

Review 9.  Improving translational research in sex-specific effects of comorbidities and risk factors in ischaemic heart disease and cardioprotection: position paper and recommendations of the ESC Working Group on Cellular Biology of the Heart.

Authors:  Cinzia Perrino; Péter Ferdinandy; Hans E Bøtker; Bianca J J M Brundel; Peter Collins; Sean M Davidson; Hester M den Ruijter; Felix B Engel; Eva Gerdts; Henrique Girao; Mariann Gyöngyösi; Derek J Hausenloy; Sandrine Lecour; Rosalinda Madonna; Michael Marber; Elizabeth Murphy; Maurizio Pesce; Vera Regitz-Zagrosek; Joost P G Sluijter; Sabine Steffens; Can Gollmann-Tepeköylü; Linda W Van Laake; Sophie Van Linthout; Rainer Schulz; Kirsti Ytrehus
Journal:  Cardiovasc Res       Date:  2021-01-21       Impact factor: 10.787

Review 10.  Cardiomyocyte Remodeling in Atrial Fibrillation and Hibernating Myocardium: Shared Pathophysiologic Traits Identify Novel Treatment Strategies?

Authors:  Brian R Weil; Cevher Ozcan
Journal:  Biomed Res Int       Date:  2015-06-29       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.